Trial Outcomes & Findings for Patient-Centered Care for the Older Adult With Hematologic Malignancy (NCT NCT02359838)

NCT ID: NCT02359838

Last Updated: 2022-07-19

Results Overview

Overall Survival at one year

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

160 participants

Primary outcome timeframe

One year

Results posted on

2022-07-19

Participant Flow

Participant milestones

Participant milestones
Measure
Usual Care
Frail/pre-frail hematologic oncology patients receive usual care Baseline Geriatric Screening/Assessment: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
Geriatrician Co-Management
Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician Baseline Geriatric Screening/Assessment: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status. Geriatrician Co-Management: A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
Overall Study
STARTED
100
60
Overall Study
COMPLETED
100
48
Overall Study
NOT COMPLETED
0
12

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Usual Care
n=100 Participants
Frail/pre-frail hematologic oncology patients receive usual care Baseline Geriatric Screening/Assessment: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
Geriatrician Co-Management
n=60 Participants
Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician Baseline Geriatric Screening/Assessment: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status. Geriatrician Co-Management: A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
Total
n=160 Participants
Total of all reporting groups
Age, Customized
80.3 years
STANDARD_DEVIATION 3.9 • n=100 Participants
80.5 years
STANDARD_DEVIATION 4.7 • n=60 Participants
80.4 years
STANDARD_DEVIATION 4.2 • n=160 Participants
Sex: Female, Male
Female
36 Participants
n=100 Participants
20 Participants
n=60 Participants
56 Participants
n=160 Participants
Sex: Female, Male
Male
64 Participants
n=100 Participants
40 Participants
n=60 Participants
104 Participants
n=160 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Frailty Status
Pre-Frail
75 Participants
n=100 Participants
49 Participants
n=60 Participants
124 Participants
n=160 Participants
Frailty Status
Frail
25 Participants
n=100 Participants
11 Participants
n=60 Participants
36 Participants
n=160 Participants

PRIMARY outcome

Timeframe: One year

Overall Survival at one year

Outcome measures

Outcome measures
Measure
Usual Care
n=100 Participants
Frail/pre-frail hematologic oncology patients receive usual care Baseline Geriatric Screening/Assessment: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
Geriatrician Co-Management
n=60 Participants
Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician Baseline Geriatric Screening/Assessment: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status. Geriatrician Co-Management: A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
Overall Survival
79 Participants
49 Participants

Adverse Events

Usual Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 21 deaths

Geriatrician Co-Management

Serious events: 0 serious events
Other events: 0 other events
Deaths: 11 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Gregory A. Abel

Dana-Farber Cancer Institute

Phone: 617-632-2304

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place